Bind Biosciences appoints Dr Ed Schnipper

pharmafile | July 6, 2010 | Appointment | Manufacturing and Production, Research and Development |  Bind Bioscience, appointment, manufacturing and production, research and development 

US biopharmaceutical company Bind Biosciences has appointed Dr Ed Schnipper as chief medical officer.

Dr Schnipper joins the company with 20 years experience across the pharma and biotech sectors, most recently at Alza, where he was responsible for the clinical development of new products.

Prior to this he was senior vice president and medical director at Sequus Pharmaceuticals and before that served at Roche in various senior clinical positions.

Advertisement

Bind is working to develop best-in-class therapeutics based on its proprietary targeted nanotechnology platform

Dr Schnipper said: “This is a tremendous opportunity to create a new class of therapeutics through the medicinal nanoengineering of both existing and new drugs.

“From my experience in developing drugs based on liposomes, I view Bind Biosciences’ targeted nanoparticle technology as an advance in developing the drugs using targeted therapeutics to increase efficacy and reduce toxicity.”

Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025

The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

Rotzinger launches modular filling and capping platform for over-the-counter products

Rotzinger PharmaPack has launched a new filling and capping platform called VarioFill, designed to handle …

AAX Biotech announces collaboration for cardiovascular antibody therapy

Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

The Gateway to Local Adoption Series

Latest content